At this crisis point in history - what could possibly create these rare and extraordinary gains?

An Arizona multi-millionaire's revolutionary initiative is 
helping average Americans  find quick and lasting stock market success.

Since the Coronavirus came into our lives this slice of the stock market has given ordinary people the chance to multiply their money by 96% in 21 days on JP Morgan.


Stocks  | June 18, 2019

These three penny stocks all get a strong buy from analysts and have a very bullish market sentiment. All three penny stocks are also predicted to double in the next 12 months.

Vista Gold Corp. (VGZ)

Vista Gold Corp. (VGZ), a Canadian gold mining company, has gained 5.80% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

Stock Score Report, InvestorsObserver’s proprietary scoring system, gives VGZ stock a score of 84 out of a possible 100. That score is chiefly influenced by a fundamental score of 88. In addition to the average rating from Wall Street analysts, VGZ stock has a mean target price of $1.95. This means analysts expect the stock to increase 167.12% over the next 12 months. VGZ’s score also includes a short-term technical score of 83. The long-term technical score for VGZ is 82.

WidePoint Corp. (WYY)

WidePoint Corp. (WYY),  a provider of managed mobility services, telecom life-cycle management, and cyber security solutions, is lower by -11.54% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

Stock Score Report, InvestorsObserver’s proprietary scoring system, gives WYY stock a score of 50 out of a possible 100. That score is chiefly influenced by a long-term technical score of 17. WYY’s score also includes a short-term technical score of 44. The fundamental score for WYY is 88. In addition to the average rating from Wall Street analysts, WYY stock has a mean target price of $1.00. This means analysts expect the stock to gain 117.39% over the next 12 months.

Dare Bioscience (DARE)

Dare Bioscience (DARE), a clinical-stage biopharmaceutical company focused on women’s reproductive health, is down -23.31% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

Stock Score Report, InvestorsObserver’s proprietary scoring system, gives DARE stock a score of 75 out of a possible 100. That score is mainly influenced by a fundamental score of 88. In addition to the average rating from Wall Street analysts, DARE stock has a mean target price of $5.88. This means analysts expect the stock to increase 476.47% over the next 12 months. DARE’s score also includes a short-term technical score of 73. The long-term technical score for DARE is 64.


A revolutionary initiative is helping average Americans find quick and lasting stock market success.

275% in one week on XLF - an index fund for the financial sector. Even 583%, in 7 days on XHB… an ETF of homebuilding companies in the S&P 500. 


{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

You might also like


Stocks | June 23

Investing | June 23

Stocks | June 22